PD-L1 is a key factor in cancer immunotherapy, and subset analyses in many clinical trials—including the CheckMate, KEYNOTE, POPLAR, and OAK studies—showed a close correlation between PD-L1 expression and the efficacy of anti-PD-1/PD-L1 inhibitors [1, 3–6, 47]. The gene discussed is CD274; the disease is cancer.